Company / Net Income
Trevi Therapeutics, Inc. Net Income History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$47.9M
FY2024
5-year range
-$47.9M / -$29.1M
FY2020-FY2024
Trend
-64.8%
vs FY2023
Sector context
#80 of 216
Health Care
What the data says
At -$48M, Trevi Therapeutics, Inc.'s net income ranks #80 of 216 in the Health Care sector. Declined from -$29M to -$48M over the past 2 years.
Based on SEC 10-K filings.
-$48M in FY2024.
Declined from -$29M to -$48M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#80 of 216 in Health CareTop 37% of 216This company -$47.9M Sector average $454.3M
▼
-110.5% below sector average
Key checks
Key Insights
- In FY2024, net income decreased 64.8% year-over-year.
- Ranks #80 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$47.9M | -64.8% |
| FY2023 | -$29.1M | +0.3% |
| FY2022 | -$29.2M | +14.1% |
| FY2021 | -$33.9M | -3.6% |
| FY2020 | -$32.8M | -25.8% |
| FY2019 | -$26.1M | -26.8% |
| FY2018 | -$20.5M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026